NumFin

Celldex Therapeutics, Inc.

Simbol: CLDX

NASDAQ

40.86

USD

Tržna cena danes

  • -15.8077

    Razmerje P/E

  • -0.2079

    Razmerje PEG

  • 2.69B

    Kapaciteta MRK

  • 0.00%

    Donos DIV

Celldex Therapeutics, Inc. (CLDX) Finančni izkazi

Download
LetniČetrtletno
LinearnoLog
Na grafu so prikazane privzete številke v dinamiki za Celldex Therapeutics, Inc. (CLDX). Prihodki podjetja prikazujejo povprečje 6.864 M, ki je 0.832 % gowth. Povprečni bruto dobiček za celotno obdobje je 3.162 M, ki je 0.925 %. Povprečno razmerje bruto dobička je 0.425 %. Rast čistega dobička za lanskoletno poslovanje podjetja je 0.152 %, kar je enako -0.692 % % v povprečju v celotni zgodovini podjetja.,

LetniČetrtletno
10Y20Y30Y40Y

Bilanca stanja

Če pogledamo fiskalno pot podjetja Celldex Therapeutics, Inc., opazimo povprečno rast sredstev. Zanimivo je, da ta stopnja znaša , kar odraža tako visoke kot tudi padce podjetja. Pri primerjavi četrtletja s četrtletjem se ta številka prilagodi na 0. Pogled nazaj v preteklo leto razkrije skupno spremembo sredstev v višini 0.320. Na področju kratkoročnih sredstev CLDX znaša 431.693 v valuti poročanja. Velik del teh sredstev, natančneje 421.698, je v denarju in kratkoročnih naložbah. V tem segmentu se je ob primerjavi s podatki za preteklo leto spremenil za 0.383%. Dolgoročne naložbe podjetja, ki sicer niso v središču njegovega zanimanja, znašajo 0, če obstajajo, v valuti poročanja. To pomeni razliko v višini 0.000% glede na zadnje obdobje poročanja, kar odraža strateške premike družbe. Dolgoročni profil podjetja kaže skupni dolgoročni dolg v višini 0.928 v valuti poročanja. Ta številka pomeni medletno spremembo v višini -0.370%. Vrednost za delničarje, kot jo prikazuje celotni lastniški kapital, je ovrednotena z vrednostjo 429.171 v valuti poročanja. Letna sprememba tega vidika je 0.316%. Podrobnejši pregled finančnih podatkov podjetja razkrije dodatne podrobnosti. Neto terjatve so ovrednotene na 4.528, zaloge na 0, dobro ime pa na 0, če obstaja. Celotna neopredmetena sredstva, če so prisotna, so ovrednotena z vrednostjo 27.19.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986

balance-sheet.row.cash-and-short-term-investments

1188.13421.7305408.3
194.4
64.4
94
139.4
189.8
289.9
201
303
84
53.3
61.1
82.5
44.3
15.7
40.9
23.4
31.7
20.3
25.1
42.7
50.2
13.6
8.9
6.4
12.6
12.3
7.6
28.3
3.3
8.7
11.3
9.6
10.8
13.5
2.4

balance-sheet.row.short-term-investments

1049.84386.9275.5369.1
150.6
53.2
69.7
99.1
147.3
217.8
173
133.6
59.1
41.4
39.8
25.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

6.214.50.30.2
1.8
1
3.2
1.9
1.8
1
0.4
0.5
0
0.2
0.3
0.5
1.8
0.3
0.3
0.4
2.2
1.5
0.2
0.3
0.2
0.4
0
0
0.4
0.3
0.6
0.5
0.7
1.1
0.7
0.6
0.4
0.3
0

balance-sheet.row.inventory

-1.430-0.3-0.2
-1.8
-1
-3.2
0
-1.8
-1
-0.4
0
0
0
-0.3
0
0
0
0
0
0
0
71.5
0.1
0.1
0
0
0
0
0.4
0.4
0.4
0.6
0.3
0.4
0.2
0.1
0
0

balance-sheet.row.other-current-assets

39.135.512.72.6
3.4
2.3
5.1
3.4
5.8
5
3.9
1.7
1.2
1.2
1.8
1
1
0.4
1.2
0.8
0.6
0.6
0.6
0.3
1.4
0.4
6.7
1
0.3
0.6
9.1
0.3
14.6
0.5
0.3
0.3
0.3
0.2
0.4

balance-sheet.row.total-current-assets

1232.04431.7317.7410.8
197.8
66.7
99.1
144.8
195.6
294.9
205
305.2
85.1
54.7
62.9
84
47.1
16.4
42.4
24.6
34.5
22.3
25.9
43.3
51.8
14.5
15.6
7.4
13.3
13.6
17.7
29.5
19.2
10.6
12.7
10.7
11.6
14
2.8

balance-sheet.row.property-plant-equipment-net

21.66.63.73.6
3.8
4
6.1
10.4
13.2
11.5
10.5
10
7.2
9.1
10.8
11.5
13.6
16.4
14
5.7
4.2
0.9
1.1
1
1
1.3
1.1
0.4
0.5
1.2
1.1
1.8
2
2
2.2
2
0.9
0.6
0.4

balance-sheet.row.goodwill

3.36000
0
0
0
91
91
9
9
9
9
9
9
9
0
1
1
1036.3
1036.3
1036.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

112.527.231.330.3
34.2
52.2
50.6
67.6
174.6
31.2
32.5
22.8
33.2
34.2
36.2
30
2.5
3.1
4
6.1
7.1
8
8.2
9.2
10.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

115.8627.231.330.3
34.2
52.2
50.6
158.6
174.6
31.2
32.5
31.8
33.2
34.2
36.2
38.9
2.5
4.1
5
6.1
7.1
8
8.2
9.2
10.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-investments

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

0.210.100
0
0
0
1.9
0
0
0
0.1
0
0
0
6
6.7
0.6
0.1
0
0
0.1
0.1
0
0
4.1
6
2
3.4
3.7
1.9
1.8
1.2
0.6
0.7
0.5
0.5
0
0

balance-sheet.row.total-non-current-assets

137.6733.93533.8
38
56.2
56.7
170.9
187.8
42.6
43
41.9
40.4
43.3
47
56.4
22.7
21.2
19.1
11.8
11.3
9
9.4
10.1
11.8
5.4
7.1
2.4
3.9
4.9
3
3.6
3.2
2.6
2.9
2.5
1.4
0.6
0.4

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

1369.71465.6352.7444.7
235.8
122.9
155.8
315.6
383.4
337.6
248
347.1
125.5
98
109.9
140.4
69.8
37.6
61.5
36.5
45.8
31.3
35.2
53.5
63.6
19.9
22.7
9.8
17.2
18.5
20.7
33.1
22.4
13.2
15.6
13.2
13
14.6
3.2

balance-sheet.row.account-payables

11.343.53.31.2
1
1.2
1.1
1.7
1.7
1.5
2.6
2.2
0.7
0.9
0.9
1.4
2.2
1.3
2.6
1.1
1.8
0.5
0.8
1.1
0.9
0.6
0.4
0.2
0.3
0.7
0.8
0.5
0.4
0.5
0.8
0
0
0
0

balance-sheet.row.short-term-debt

6.181.61.41.7
1.3
1.9
4.5
6.6
0
4.4
2.6
0
5.6
6.4
1.1
2.2
0.2
0.6
0.5
0.2
3.5
0
0
0
0.3
0.3
1
0.8
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

6.110.92.61.3
2.2
1.7
0
0
0
-21.2
0
0
5.7
9
8.9
11.7
0.8
4.6
4.2
0
0
0
0
0
0
0.3
0.6
0.8
0
0.2
0.5
0.5
0
0
0
0
0
0
0

Deferred Revenue Non Current

0000
0
0
0
0
0
16.6
0
0
0
0
0
34.2
36488.7
42270.4
45069.1
0
0
0
0
2693.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

41.582613.81.6
3.4
2
4.5
6.6
33.5
4.4
2.6
18.1
0.4
7
13.2
5.6
6.9
3.1
2.7
-9997.7
0.2
1.5
2.1
2.7
4.2
1.3
1.9
1.8
1.3
1.7
1.8
2.9
2
2.3
1.7
2.5
1.3
1.7
0.5

balance-sheet.row.total-non-current-liabilities

23.725.37.98.7
12.3
17.3
19.1
51.5
82.7
17.2
11.9
7
12.1
15
14.5
52.2
37.6
46.9
49.2
11.9
1.9
1.9
0.5
2.7
4.2
0.3
0.6
0.7
0.3
0.1
0.5
0.6
0.4
0.5
0.8
2.3
2.4
2.5
5.2

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1.9
0
0
0
0
0
0
-0.3
0
0
0
-0.4
-0.5
-0.8
0
0
0
0

balance-sheet.row.capital-lease-obligations

10.680.943
3.5
3.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

113.5536.526.525.2
26.5
28.9
31.7
79.3
117.9
47.5
36.4
27.3
29.8
29.3
34.7
66.6
51.7
56.7
59.3
15.6
7.4
3.4
3.9
8.2
9.6
2.5
3.9
3.5
1.6
2.5
3.1
4
2.4
2.8
2.5
4.8
3.7
4.2
5.7

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.3
1.7
0
0
0
0

balance-sheet.row.common-stock

0.20.100
0
0
0
0.1
0.1
0.1
0.1
0.1
0.1
0
0
0
0
0
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

-5352.5-1397.4-1255.9-1143.6
-1073.1
-1013.3
-962.4
-812.5
-719.5
-591
-463.8
-345.7
-264.1
-205
-160.2
-157.7
-121.1
-277.9
-256.2
-235.9
-217.8
-204.6
-191.9
-178.1
-155.3
-133.3
-122
-70.2
-57.1
-46.3
-38.1
-26.5
-18.7
-10.5
-7
-6
-4.9
-3.7
-2.9

balance-sheet.row.accumulated-other-comprehensive-income-loss

9.643.31.31.9
2.6
2.6
2.6
2.6
2.5
2.3
2.6
2.7
2.7
2.7
2.8
2.5
2.6
0.1
-5.4
-1.2
-1.5
-1
-4.4
-4
-4.1
-3.5
-2.9
-2.7
-2.5
-3.2
-3
-3.3
0
-1.7
-1.2
-0.7
-0.5
-0.2
-0.1

balance-sheet.row.other-total-stockholders-equity

6598.841823.21580.81561.1
1279.8
1104.7
1083.9
1046.2
982.3
878.7
672.7
662.7
357.1
271
232.7
228.9
136.7
258.8
263.7
257.9
257.6
233.4
227.6
227.2
213.3
154.2
143.7
79.2
75.2
65.5
58.7
58.9
38.4
22.3
19.6
15.1
14.7
14.3
0.5

balance-sheet.row.total-stockholders-equity

1256.17429.2326.2419.5
209.4
94
124.1
236.4
265.4
290.1
211.7
319.8
95.8
68.7
75.3
73.8
18.1
-19
2.2
20.9
38.4
27.9
31.3
45.3
53.9
17.4
18.8
6.3
15.6
16
17.6
29.1
19.7
10.4
13.1
8.4
9.3
10.4
-2.5

balance-sheet.row.total-liabilities-and-stockholders-equity

1369.71465.6352.7444.7
235.8
122.9
155.8
315.6
383.4
337.6
248
347.1
125.5
98
109.9
140.4
69.8
37.6
61.5
36.5
45.8
31.3
35.2
53.5
63.6
19.9
22.7
9.8
17.2
18.5
20.7
33.1
22.4
13.2
15.6
13.2
13
14.6
3.2

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.3
0
0
0
0
0
0

balance-sheet.row.total-equity

1256.17429.2326.2419.5
209.4
94
124.1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

1369.71---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

1049.84386.9275.5369.1
150.6
53.2
69.7
99.1
147.3
217.8
173
133.6
59.1
41.4
39.8
25.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-debt

12.292.543
3.5
3.7
4.5
6.6
0
4.4
2.6
0
11.3
15.4
10
13.8
1
5.2
4.6
0.2
2.1
0
0
0
0.3
0.6
1.6
1.6
0
0.2
0.5
0.5
0
0
0
0
0
0
0

balance-sheet.row.net-debt

-126-32.3-25.4-36.1
-40.4
-7.6
-19.8
-33.7
-42.5
-67.7
-25.4
-169.4
-13.6
3.5
-11.3
-43.2
-43.3
-10.5
-36.3
-23.2
-29.6
-20.3
-25.1
-42.7
-49.9
-13.1
-7.3
-4.8
-12.6
-12.1
-7.1
-27.8
-3.3
-8.7
-11.3
-9.6
-10.8
-13.5
-2.4

Izkaz denarnih tokov

V zadnjem obdobju se je v finančnem okolju Celldex Therapeutics, Inc. opazno spremenil prosti denarni tok, ki se je spremenil v -0.034. Podjetje je nedavno povečalo svoj osnovni kapital z izdajo 218.46, kar kaže na razliko 19.149 v primerjavi s prejšnjim letom. Zanimivo je, da je del delnic podjetja, natančneje 0, odkupilo podjetje samo. To dejanje je povzročilo spremembo v 0.000 v primerjavi s prejšnjim letom. Medtem pa obveznosti podjetja trenutno znašajo 9.38 v valuti poročanja. Družba je pri naložbenju porabila neto denarna sredstva v višini -105782000.000 v valuti poročanja. To je premik za -2.176 v primerjavi s prejšnjim letom. V istem obdobju je družba zabeležila 3.01, 0 in 0, ki so pomembne za razumevanje naložbenih in odplačilnih strategij podjetja. Družba je pri financiranju porabila 0.000, pri čemer je razlika v primerjavi z letom prej znašala 0.000. Poleg tega je podjetje namenilo 0 za izplačilo dividend svojim delničarjem. Hkrati je izvajalo tudi druge finančne manevre, imenovane 0, ki so prav tako pomembno vplivali na denarni tok v tem obdobju. Te sestavine skupaj tvorijo celovito sliko finančnega stanja podjetja in strateškega pristopa k upravljanju denarnih tokov.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996199519941993199219911990198919881987

cash-flows.row.net-income

-141.43-141.4-112.3-70.5
-59.8
-50.9
-151.2
-93
-128.5
-127.2
-118.1
-81.5
-59.1
-44.8
-2.5
-36.5
-47.5
-21.6
-20.4
-18.1
-13.2
-12.7
-13.8
-22.8
-22
-11.3
-51.8
-13.1
-10.8
-8.3
-11.6
-7.8
-3.6
-3.4
-1
-1.1
-1.2
-0.8

cash-flows.row.depreciation-and-amortization

3.0132.93.1
3.9
4.9
3.8
5.3
4.1
4
3.4
2.9
3.1
4.2
5.9
3.5
2.5
2.7
2.1
2.1
1.7
1.5
1.6
2.3
1.3
2
1
0.4
0.5
0.7
0.8
0.9
0.6
0.6
0.5
0.3
0.2
0.2

cash-flows.row.deferred-income-tax

0-22.8-0.2-0.2
-1.2
0.7
-0.8
-24.3
1
0.3
0.1
-1.4
-0.7
0
-0.1
-0.5
-4815.7
-359.1
-1626.8
-538
-328
-115
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

23.8923.915.69
3.9
4.6
8.1
12.3
15.3
12.8
6.9
4.5
2.3
2.3
2.8
3.1
4815.7
359.5
1626.8
538
328
115
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

13.4613.5-3.9-1.1
-0.3
-4.3
-15.4
-12.2
-6.6
10.9
6.1
7.7
4.4
2.4
-37.2
0.9
43.3
-1.3
43.7
10
1.1
-1.8
-4.5
-0.4
7.2
0.7
-2.8
-0.2
-0.8
-0.2
-0.9
1.8
-0.7
-0.3
-0.2
10
-10
12.3

cash-flows.row.account-receivables

-2.28-2.3-0.21.6
-0.8
-0.8
-0.8
-0.1
-0.8
0
0.1
-0.4
0.1
0.2
1.3
1.3
-1655.6
286.8
97.4
1812
-757.5
-1241.9
-113.7
-113.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

0000
0
13.9
1.8
-3.6
-0.7
0
0
0.6
2.3
0.2
-0.3
0.7
443.9
532.6
-1807.9
-193.3
-2566
2247.7
0.1
0
0
0
0
0
0
0
0
0.2
0
0.1
-0.2
0
0
0

cash-flows.row.account-payables

9.389.43.13.7
1.6
-13.1
-13.1
-8.7
-5
0
0
7.2
2.1
2.1
-2.5
-2.5
1221.3
-819.1
1751.3
-1618.7
3323.5
-1005.8
278.2
278.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

9.386.4-6.8-6.3
-1.1
-4.3
-3.3
0.2
-0.1
10.9
6.1
0.3
-0.1
-0.1
-35.7
1.4
33.8
-1.6
2.8
10
1.1
-1.8
-169
-164.9
7.1
0.7
-2.8
-0.2
-0.8
-0.2
-0.9
1.6
-0.7
-0.4
0
10
-10
0

cash-flows.row.other-non-cash-items

-6.2216.6-5.8-1.1
13
-1.3
80.2
12
1.6
0.3
0.1
0.1
0.2
0.3
0.7
-0.3
19.9
0.5
1.6
0
0
1.2
0
0.1
9.1
0.1
44.7
5.2
1.4
-0.1
2.6
-0.4
-0.2
0.1
0
-9.2
11
-11.7

cash-flows.row.net-cash-provided-by-operating-activities

-107.29000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-1.82-1.8-1.8-1.2
-1.6
-0.7
-0.8
-1.8
-2.8
-4.9
-1.9
-4.2
-0.3
-0.5
-2.1
-0.5
-1.3
-5
-9.3
0
0
-0.2
-0.6
-0.6
-0.2
-0.7
-0.3
-0.1
-0.6
-0.6
-0.8
-0.5
-0.5
-0.4
-0.7
0
0
0

cash-flows.row.acquisitions-net

-13.3800.10
0.1
0
0
1.8
4.6
0
0
0
0
0
0
51.7
11
0
0
-2.2
-3.7
0
0
0
-0.7
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

-424.56-424.6-189-389.9
-220.3
-95.4
-171.2
-171
-175.7
-206.4
-148.3
-112.1
-69.3
-52.7
-56.5
-9.6
0
0
0
0
-2
0
0
0
0
0
0
0
0
0
-1.2
0
-2.5
0
0
0
0
0

cash-flows.row.sales-maturities-of-investments

320.6320.6280.7174.9
123.6
113.2
201.5
219.2
242.8
161.1
109.2
38.9
52.4
51
42.4
3.5
0
0
0
0
4
0
0
0
0
4.9
4.5
0
0
8.5
14
13
0
0
0
0
0
0

cash-flows.row.other-investing-activites

13.38000
0
0
0.3
-1.8
0
0
0
0
0.2
0.1
0.1
0
0.5
-0.7
0
0
0
-2
-0.3
-0.2
-0.1
-0.9
3.4
1.6
0.4
-2
-0.4
-0.7
-0.6
0
-0.2
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

-105.78-105.889.9-216.2
-98.2
17.1
29.8
46.5
68.9
-50.2
-41
-77.4
-17
-2.2
-16.2
45.1
10.2
-5.7
-9.3
-2.2
-1.7
-2.2
-0.8
-0.8
-1
3.3
7.6
1.5
-0.2
5.9
11.6
11.8
-3.6
-0.4
-0.9
0
0
0

cash-flows.row.debt-repayment

0000
-3
0
0
0
0
0
0
-11
-4
-12.5
-0.2
-3.1
-102.4
-244.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

218.46218.54.1269.9
170.8
16.2
29
51
13.9
188.8
0
295.7
83.8
36
1
0.7
10.9
0
0
0
23.4
9.2
0
14.1
42
10
3.7
0
10.2
6.6
0
17.2
0.3
0.8
3.4
0
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-0.1
-0.1
0
0
0
0
0
0
-0.1
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

0.6904.12.5
3.4
0
0.4
0.3
0.5
4.3
1.2
4.9
-0.1
4.9
10
0
102.4
244.1
-0.2
-0.2
2.1
0
0
0
0
0
0
0
0
0.2
0
0.5
0
0
0
0
0
0

cash-flows.row.net-cash-used-provided-by-financing-activities

218.46218.54.1272.4
171.2
16.3
29.4
51.3
14.5
193.2
1.2
289.6
79.8
28.4
10.8
-2.5
10.9
-0.2
-0.2
-0.1
25.5
9.1
-0.1
14.1
42
10
3.7
0
10.2
6.7
0
17.7
0.3
0.8
3.4
0
0
0

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.1
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

5.385.4-9.7-4.7
32.6
-13.1
-16
-2.2
-29.6
44.1
-141.4
144.5
13
-9.4
-35.7
12.7
39.3
-25.3
17.5
-8.3
13.5
-4.8
-17.6
-7.5
36.6
4.7
2.5
-6.2
0.3
4.7
2.5
24
-7.2
-2.6
1.8
0
0
12.3

cash-flows.row.cash-at-end-of-period

138.2934.829.439.1
43.8
11.2
24.3
40.3
42.5
72.1
28
169.4
24.9
11.9
21.3
57
44.3
15.7
40.9
23.4
31.7
20.3
25.1
42.7
50.2
13.6
8.9
6.4
12.6
12.3
7.7
28.3
3.4
8.7
11.4
0
0
12.3

cash-flows.row.cash-at-beginning-of-period

132.9129.439.143.8
11.2
24.3
40.3
42.5
72.1
28
169.4
24.9
11.9
21.3
57
44.3
4.9
40.9
23.4
31.7
18.3
25.1
42.7
50.2
13.6
8.9
6.4
12.6
12.3
7.6
5.2
4.3
10.6
11.3
9.6
0
0
0

cash-flows.row.operating-cash-flow

-107.29-107.3-103.7-60.9
-40.4
-46.4
-75.2
-99.9
-113
-98.9
-101.5
-67.7
-49.8
-35.7
-30.4
-29.9
18.3
-19.3
27
-6
-10.3
-11.7
-16.7
-20.8
-4.4
-8.5
-8.9
-7.7
-9.7
-7.9
-9.1
-5.5
-3.9
-3
-0.7
0
0
12.3

cash-flows.row.capital-expenditure

-1.82-1.8-1.8-1.2
-1.6
-0.7
-0.8
-1.8
-2.8
-4.9
-1.9
-4.2
-0.3
-0.5
-2.1
-0.5
-1.3
-5
-9.3
0
0
-0.2
-0.6
-0.6
-0.2
-0.7
-0.3
-0.1
-0.6
-0.6
-0.8
-0.5
-0.5
-0.4
-0.7
0
0
0

cash-flows.row.free-cash-flow

-109.11-109.1-105.6-62.2
-42
-47.1
-76
-101.7
-115.8
-103.8
-103.5
-71.9
-50.1
-36.2
-32.5
-30.4
17
-24.3
17.7
-6
-10.3
-11.9
-17.2
-21.4
-4.6
-9.2
-9.2
-7.8
-10.3
-8.5
-9.9
-6
-4.4
-3.4
-1.4
0
0
12.3

Vrstica izkaza poslovnega izida

Prihodki Celldex Therapeutics, Inc. so se v primerjavi s prejšnjim obdobjem spremenili za 1.920%. Bruto dobiček podjetja CLDX znaša 3.88. Odhodki iz poslovanja podjetja so 145.92 in so se v primerjavi s prejšnjim letom spremenili za 33.315%. Odhodki za amortizacijo znašajo 3.01, kar je -0.775% sprememba glede na zadnje obračunsko obdobje. Stroški poslovanja so sporočeni v višini 145.92, ki kaže 33.315% spremembo glede na preteklo leto. Stroški prodaje in trženja znašajo 0, kar pomeni 0.000% spremembo v primerjavi s preteklim letom. EBITDA na podlagi zadnjih podatkov znaša 0 in predstavlja -0.233% rast v primerjavi s preteklim letom. Prihodki iz poslovanja so -142.04, ki kažejo 0.233% spremembo v primerjavi s preteklim letom. Sprememba čistih prihodkov je 0.152%. Čisti prihodki v zadnjem letu so znašali -141.43.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986

income-statement-row.row.total-revenue

6.886.92.44.7
7.4
3.6
9.5
12.7
6.8
5.5
3.6
4.1
11.2
9.3
46.8
15.2
7.5
5.1
4.9
3.1
6.9
4.6
6.7
3.3
0.8
1.5
2.2
1.2
1.1
4
7
9
6.6
10.2
10.9
7.8
4.6
2.2
0.1

income-statement-row.row.cost-of-revenue

3.0131.43.1
42.5
42.7
0
0
0
0
0
2.3
10.8
9.1
12.1
8.4
0
0
0
0
0
0
0
0
-0.7
-0.7
-0.4
-0.3
-0.1
1.2
1.2
1.5
0.6
1.1
0.8
0.8
0.3
-0.1
0

income-statement-row.row.gross-profit

3.883.911.6
-35.1
-39.1
9.5
12.7
6.8
5.5
3.6
1.8
0.4
0.1
34.7
6.8
7.5
5.1
4.9
3.1
6.9
4.6
6.7
3.3
1.5
2.2
2.6
1.5
1.2
2.8
5.8
7.5
6
9.1
10.1
7
4.3
2.3
0.1

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

117.25---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

30.91---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

130.23130.290.355.4
54
42.7
0.2
0.9
1
1
1
1
1.1
1.9
3.1
0.3
0.4
1
1
1
1
1
0.8
1.4
1.3
2
1
0.4
0.5
0.7
0.8
0.9
0.6
0.6
0.5
0.3
0.2
0.2
0.1

income-statement-row.row.operating-expenses

148.17145.9109.573.8
57
58.1
85.9
122.1
139.7
135
126
83.2
58.5
43.6
41.2
43.6
41.5
28
27.3
22
20.4
16.4
21.1
27.9
16.9
14.1
10.5
9.2
13
14.6
15.3
16.9
10.7
13.5
12
8.6
6.3
3.9
2

income-statement-row.row.cost-and-expenses

148.93148.9109.573.8
57
58.1
85.9
122.1
139.7
135
126
85.6
69.3
52.7
53.2
52
41.5
28
27.3
22
20.4
16.4
21.1
27.9
16.2
13.4
10.1
8.9
12.9
15.8
16.5
18.4
11.3
14.6
12.8
9.4
6.6
3.8
2

income-statement-row.row.interest-income

13.1113.12.90.5
2.4
4.2
0
0
0
0
0
0
0.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.interest-expense

00-2.90
0
0
151.1
16
0
0
0
0.9
1.6
1.8
1.3
0.5
0
-2.2
-4.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0.610.62.90.5
2.4
4.2
-75.5
-8
4.4
2.3
4.3
0.8
0.5
0.4
5.3
0.2
-13.5
1.1
2.1
0.8
0.4
0.2
0.6
1.8
-6.5
0.6
-43.8
-5.5
1
3.6
-2.1
1.2
0.8
0.9
0.8
0.7
0.8
0.9
0.1

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

130.23130.290.355.4
54
42.7
0.2
0.9
1
1
1
1
1.1
1.9
3.1
0.3
0.4
1
1
1
1
1
0.8
1.4
1.3
2
1
0.4
0.5
0.7
0.8
0.9
0.6
0.6
0.5
0.3
0.2
0.2
0.1

income-statement-row.row.total-operating-expenses

0.610.62.90.5
2.4
4.2
-75.5
-8
4.4
2.3
4.3
0.8
0.5
0.4
5.3
0.2
-13.5
1.1
2.1
0.8
0.4
0.2
0.6
1.8
-6.5
0.6
-43.8
-5.5
1
3.6
-2.1
1.2
0.8
0.9
0.8
0.7
0.8
0.9
0.1

income-statement-row.row.interest-expense

00-2.90
0
0
151.1
16
0
0
0
0.9
1.6
1.8
1.3
0.5
0
-2.2
-4.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

-0.83313.43.7
25.2
-3.1
0.2
5.3
1
1
1
2.9
1.1
1.9
3.1
3.5
2.5
2.7
2.1
2.1
1.7
1.5
1.6
2.3
1.3
2
1
0.4
0.5
0.7
0.8
0.9
0.6
0.6
0.5
0.3
0.2
0.2
0.1

income-statement-row.row.ebitda-caps

-149.31---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-142.04-142-115.2-71.2
-63.4
-55
-156.4
-121.5
-132.9
-129.5
-122.4
-81.4
-58.1
-43.4
-6.5
-36.9
-48.8
-22.9
-22.4
-18.9
-13.6
-11.7
-14.4
-24.6
-15.4
-11.9
-7.9
-7.7
-11.8
-11.8
-9.5
-9.4
-4.7
-4.4
-1.9
-1.6
-2
-1.6
-1.9

income-statement-row.row.income-before-tax

-141.43-141.4-112.3-70.7
-60.9
-50.9
-151.9
-117.3
-128.5
-127.2
-118.1
-81.5
-59.1
-44.8
-2.5
-37.1
-62.3
-21.8
-20.3
-18.1
-13.2
-11.5
-13.8
-22.8
-22
-11.3
-7.9
-13.2
-10.8
-8.2
-11.6
-8.2
-3.9
-3.5
-1.1
-0.9
-1.2
-0.7
-1.8

income-statement-row.row.income-tax-expense

0010.5-0.2
-1.2
-0.5
-0.8
-24.3
-8.8
-2.3
-4.3
-0.8
-0.5
-0.4
-5.3
-0.5
27
-0.1
0.1
-1.5
-0.8
0.7
-1.2
-3.6
13.1
-1.3
87.7
10.9
-2
-7.1
4.2
-2.8
-1.9
-1.9
-1.7
-1.2
-1.6
-1.7
-0.3

income-statement-row.row.net-income

-134.48-141.4-122.8-70.5
-59.8
-50.4
-151.2
-93
-128.5
-127.2
-118.1
-81.5
-59.1
-44.8
-2.5
-36.5
-47.5
-21.6
-20.4
-18.1
-13.2
-12.7
-13.8
-22.8
-22
-11.3
-51.8
-13.1
-10.8
-8.3
-11.6
-7.8
-3.6
-3.4
-1
-1.1
-1.2
-0.8
-1.7
Podobne delnice
Morda vas zanima tudi:
SRNE
Sorrento Therapeutics, Inc..
0.014 USD
NASDAQ
MRVI
Maravai LifeSciences Holdings, Inc..
8.8 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.03 USD
NASDAQ
GUBRA.CO
Gubra A/S.
296 DKK
CPH
T5O.DE
CytoTools AG.
0.468 EUR
XETRA
HBC.OL
Hofseth BioCare ASA.
2.04 NOK
OSL
6826.HK
Shanghai Haohai Biological Technology Co., Ltd..
42.05 HKD
HKSE
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ

Pogosto zastavljeno vprašanje

Kaj je Celldex Therapeutics, Inc. (CLDX) skupna sredstva?

Celldex Therapeutics, Inc. (CLDX) skupna sredstva so 465627000.000.

Kakšen je letni prihodek podjetja?

Letni prihodki so 5648000.000.

Kolikšna je stopnja dobička podjetja?

Dobiček podjetja je 0.563.

Kakšen je prosti denarni tok podjetja?

Prosti denarni tok je -2.097.

Kolikšna je neto stopnja dobička podjetja?

Čista stopnja dobička je -19.538.

Kolikšni so skupni prihodki podjetja?

Celotni prihodki so -20.637.

Kaj je Celldex Therapeutics, Inc. (CLDX) čisti dobiček (čisti dobiček)?

Čisti dobiček (čisti prihodek) je -141429000.000.

Kolikšen je skupni dolg podjetja?

Skupni dolg je 2542000.000.

Kolikšni so stroški poslovanja?

Stroški poslovanja so 145917000.000.

Kolikšno je število denarnih sredstev podjetja?

Denarna sredstva podjetja so 34814000.000.